Claritas Gaining Global Rights to R-107, Varied Nitric Oxide PAH Therapy
Claritas Pharmaceuticals has signed a letter of intent with the Salzman Group to acquire exclusive global rights to develop and market R-107 — a liquid form of nitric oxide — to treat, and possibly reverse, pulmonary arterial hypertension (PAH). The agreement is expected to come into effect by May…